Tag: DCBs

Two-year Ranger DCB data demonstrate “sustained, high rate” of device efficacy

Patients treated with the Ranger drug-coated balloon (DCB; Boston Scientific) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year...

IN.PACT AV DCB sustained “superior” effectiveness in subgroups with high reintervention...

Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB; Medtronic) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of...

Episode 2: Are all peripheral drug-coated balloons created equal?

 “Not all Drug-Coated Balloons (DCBs) are created equal”, Juan Granada (New York, USA), tells Vascular News in this second episode of a five-part series on the history of DCBs. Granada discusses why there...

A New DCB Era of Safety and Efficacy

In this supplement: -SAFEPAX: No drug coating pitfalls -Why the RAPID trial is of clinical importance for a paradigm shift -Vascular access rescue with...